Vascular Risk After Kidney Transplantation
2 other identifiers
observational
338
1 country
1
Brief Summary
Hypothesis: Nontraditional risk factors, such as inflammation, vitamin D deficiency, elevated PTH, insulin resistance, homocysteine, or uric acid, contribute to cardiovascular disease progression after kidney transplant. The purpose of this study is to evaluate which traditional and nontraditional cardiovascular disease risk factors best predict progression of cardiovascular disease (CVD) using carotid intima media thickness performed by ultrasound, in kidney transplant patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2006
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2006
CompletedFirst Submitted
Initial submission to the registry
September 8, 2006
CompletedFirst Posted
Study publicly available on registry
September 11, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 26, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
June 20, 2023
CompletedResults Posted
Study results publicly available
August 9, 2023
CompletedOctober 2, 2023
September 1, 2023
6.3 years
September 8, 2006
June 19, 2023
September 25, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Carotid Intima Media Thickness (CIMT)
CIMT was defined by ultrasound. The mean and standard error of a 3 year change in CIMT was assessed (between baseline and three year follow up).
3 years (baseline and three year follow up)
Eligibility Criteria
Transplant Clinic patients
You may qualify if:
- Kidney transplant more than 6 months ago
- years or older
You may not qualify if:
- Estimated GFR \<30
- Previous small bowel, or lung transplant
- Pancreas transplant less than 6 months ago
- Cancer or any condition that would change weight dramatically in the near future such as malabsorption.
- Willing to return for testing annually for 3 years
- Women who are pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Jennifer Larsen
- Organization
- University of Nebraska Medical Center
Study Officials
- PRINCIPAL INVESTIGATOR
Jennifer L Larsen, MD
University of Nebraska
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 8, 2006
First Posted
September 11, 2006
Study Start
April 1, 2006
Primary Completion
July 26, 2012
Study Completion
June 20, 2023
Last Updated
October 2, 2023
Results First Posted
August 9, 2023
Record last verified: 2023-09